Navigation Links
BioCrossroads Invests in Innovative Biotech Targeting Challenging Diseases
Date:12/23/2010

iana Finance Authority and the Indiana Economic Development Corporation.  The Seed Fund provides working capital in the range of $50,000$500,000 to promising Indiana life sciences companies at the preliminary stages of operation.

About Aarden

Aarden (www.aardenpharma.com) is a small molecule drug discovery and development company.  The company's novel technology from the labs of the Indiana University School of Medicine is a chemistry breakthrough that will enable it to make drugs against a previously undruggable set of intracellular phosphatase (PTP) disease targets. Aarden's first programs are focused on infectious disease, cancer, metabolic and autoimmune conditions.  


'/>"/>
SOURCE BioCrossroads
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioCrossroads Indiana Seed Fund Invests in Vaccine Biotech Company
2. BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimers Disease
3. Orthopedics Entrepreneur Named BioCrossroads Watanabe Life Sciences Champion of the Year
4. Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure
5. Lockheed Martin Invests in Smart Grid Research and Development at Penn State University
6. Burrill & Company Invests in Taiwan Liposome Company
7. University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer
8. The Pittsburgh Life Sciences Greenhouse Invests $725K in Portfolio Companies
9. Syngenta Ventures Invests in U.S. Biotech Company Metabolon
10. BR Ventures Invests in Semprae Laboratories
11. Federal grant invests in nanostructured super materials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... Industry Analysis, Size, Share, Growth, Trends and Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is a ... RNA) into cells. This technology helps the cells to ... metabolism by affecting the nuclear genes. The transfection technology ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... 10, 2014 Women in the ... to an additional family planning option. Sayana® Press ... at all levels of the health system and ... a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with ... is the first of four African countries expected ...
(Date:7/10/2014)... 2014 Understanding the need for better ... and the gap that currently exists in this area, ... industry-leading portfolio of validated ion channel and GPCR cell ... lines, as ion channels control many critical physiological functions ... creates the potential to treat a variety of human ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... Fla., Dec. 6, 2010 Investigators report no evidence of ... in a gene therapy trial using a vector under development ... (University College London) to correct the inherited bleeding disorder. ... test, with low and intermediate doses of the vector expected ...
... 6, 2010 See video from Novartis at: ... Novartis announced 24-month data showing that Tasigna® (nilotinib) ... of adult patients with newly diagnosed Philadelphia chromosome-positive ... These new data, from the first Phase III ...
... Cell Therapeutics, Inc. ("the Company") (Nasdaq and MTA: ... follow up results from the Company,s pivotal phase III ... Company,s recent Marketing Authorization Application (the "MAA") currently under ... The end-of-study results showed continued improvement in the trial,s ...
Cached Biology Technology:Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 2Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 3Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 4New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 2New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 3New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 4New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 5New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 6
(Date:7/10/2014)... -- Smart technology emphasis grows in biometrics sector ... NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: EBAY ... (NASDAQ: AAPL ), Visa Inc. (NYSE: ... (OTCQB: NXTD) a biometric authentication company focused on the growing ... of 30 second spots on CNBC for its next generation ...
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
(Date:7/10/2014)... According to the new market ... Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application ... & Finance), and Geography - Global Trends & Forecasts ... Fingerprint Sensors Market is projected to cross $14.35 Billion ... from 2014 to 2020. Browse more than ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... with atrial fibrillation are often treated with anticoagulants to ... dose and patients have to have their blood tested ... of Gothenburg and Chalmers University of Technology have now ... risk assessments. Atrial fibrillation, or irregular heartbeat, ...
... day of competition in London, a team of four ... emerged as the winners of this year,s Biotechnology Young ... Biotechnology Young Entrepreneurs Scheme (YES) competition are Ben Owens, ... University of Oxford. The team pitched their ...
... industry is booming more and more solar modules ... plants are increasingly feeding power into the grid. Multi-junction ... can achieve efficiencies of up to 43 percent - ... crystalline silicon. The trick: they consist of several semi-conductor ...
Cached Biology News:New method for safer dosing of anticoagulants 2Winning early-career researchers excel in entrepreneurship 2Winning early-career researchers excel in entrepreneurship 3Fraunhofer researchers receive the Franco-German Business Award 2011 2
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
...
Biology Products: